Sign In
Buy FHTX
$4.53
-0.210 (-4.43%)
At Close: Jul 31, 2026
Vanguard Group Inc. Purchases 276,444 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX)
09:14am, Friday, 19'th Nov 2021 Transcript Daily
Vanguard Group Inc. grew its position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) by 67.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 683,778 shares of the companys stock after purchasing an additional 276,444 shares during the quarter. Vanguard Group Inc. owned approximately 1.86% of []
Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
04:05pm, Wednesday, 01'st Sep 2021
CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression
Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609
07:00am, Monday, 23'rd Aug 2021
FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9
Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference
08:30am, Tuesday, 03'rd Aug 2021
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically deter
Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021
08:36am, Friday, 09'th Jul 2021
CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically deter
Foghorn Therapeutics Appoints Ian Smith to its Board of Directors
07:00am, Wednesday, 28'th Apr 2021
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically dete
Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?
09:06am, Thursday, 01'st Apr 2021
Foghorn Therapeutics (FHTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
FHTX Stock Price Increased 36.61%: Why It Happened
08:45am, Sunday, 21'st Mar 2021
The stock price of Foghorn Therapeutics Inc. (NASDAQ: FHTX) increased by 36.61% on March 19. This is why it happened.
UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021
05:11pm, Thursday, 11'th Mar 2021
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically dete
Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021
04:01pm, Thursday, 11'th Mar 2021
CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically dete
Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference
08:04am, Monday, 22'nd Feb 2021
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically deter
U.S. IPO Week Ahead: 6 IPOs Squeeze In Before The Thanksgiving Holiday
01:53pm, Saturday, 14'th Nov 2020
US IPO market activity is picking back up ahead of the Thanksgiving holiday, with six IPOs scheduled to raise $3.4 billion in the week ahead. Biotech research product provider Maravai LifeSciences pla
